FDA approves GSK and Theravance COPD drug

Share this article:

US regulators approved Anoro Ellipta, an inhaled lung drug treatment for use in COPD. The drug—developed in tandem by Glaxo and Theravance—carries a black box warning for an increased risk of asthma-related death. In September, an advisory panel endorsed the drug 11-2. Analysts forecast annual sales of Anoro Ellipta at $2.65 billion by 2018, according to Thomson Reuters.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.